These include 1 patient with PD-1–relapsed microsatellite-stable colorectal cancer who had experienced stable disease previously with a combination of anti–PD-1 and anti-cytotoxic T-lymphocyte antigen 4, 1 patient with PD-1–naive alveolar sarcoma, 1 patient with PD-1–relapsed urothelial cancer who had stable disease to prior anti–PD-1, and 2 patients with PD-1–naive ovarian cancer. This evidence concerns the gene PDCD1 and ovarian carcinoma.